Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Emerson A LimJohanna C BendellGerald S FalchookTodd M BauerCharles G DrakeJennifer H ChoeDaniel J GeorgeJanet L KarlixSusanna V UlahannanKris F SachsenmeierDeanna L RussellGanesh MoorthyBen S SiddersElizabeth A PillingHuifang ChenMaureen M HattersleyMayukh DasRakesh KumarGayle P PouliotManish R PatelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
AZD4635 monotherapy or combination therapy was well tolerated. Objective responses support additional phase II combination studies in patients with mCRPC.